A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis

Conditions

Rheumatoid Arthritis (RA)

Keywords

Rheumatoid Arthritis, Upadacitinib, RINVOQ

Brief summary

Rheumatoid Arthritis (RA) is an inflammatory disease of the joints causing pain, stiffness, swelling and loss of joint function. Despite the range of treatment options for RA steadily increasing, many patients remain sub-optimally managed, with sustained clinical remission rarely achieved. This study will assess the treatment patterns, achievement of treatment targets and maintenance of response. Upadacitinib is a drug approved for the treatment of moderately to severely active rheumatoid arthritis. Adult participants with moderate to severe RA who have been prescribed upadacitinib by their physicians will be enrolled. Approximately, 1660 participants will be enrolled this study, worldwide. Participants will not receive Upadacitinib as part of this study, but will be followed for response to treatment for up to 24 months. There may be higher burden for participants in this trial compared to their standard of care. Participants will attend regular visits, every 3 months, during the course of the study at a hospital or clinic and will be asked to provide additional information by questionnaire at each visit.

Caterina Baldi, Eleonora Celletti, Serena Bugatti, M. Govoni, Massimiliano Cazzato et al. (25 authors)

Rheumatology and Therapy2026-04-12

10.1007/s40744-026-00845-2

Achievement and Maintenance of Disease Targets with Upadacitinib in Rheumatoid Arthritis: 2-Year Outcomes from the UPHOLD Real-World Study

Andrew Östör, Eugen Feist, P. Sidiropoulos, Jérôme Avouac, Martín Rebella et al. (15 authors)

Rheumatology and Therapy2026-03-19

10.1007/s40744-026-00826-5

Sleep improvement in patients with rheumatoid arthritis treated with upadacitinib in real-world practice: results from the SLEERA study

Thomas Hügle, Heino Prillwitz, Godehard Scholz, Diego Kyburz, Jean Dudler et al. (10 authors)

Arthritis Research & Therapy2026-02-27

10.1186/s13075-026-03766-1

Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study

Andrew J.K. Östör, Eugen Feist, Prodromos Sidiropoulos, Jérôme Avouac, Martín Rebella et al. (12 authors)

Arthritis Research & Therapy2025-04-107 citations

10.1186/s13075-025-03528-5

AB0200 IMPROVEMENT OF SLEEP IMPAIRMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS ACHIEVING REMISSION OR PAIN RELIEVE WITH UPADACITINIB: RESULTS FROM THE POST-MARKETING OBSERVATIONAL SLEERA STUDY

Thomas Hügle, H. Prillwitz, B. Moeller, Diego Kyburz, Jean Dudler et al. (9 authors)

2023-05-30

10.1136/annrheumdis-2023-eular.3146

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Confirmed diagnosis of moderate to severe active Rheumatoid Arthritis (RA). * Physician decision on patient treatment with upadacitinib must have been reached prior to and independently of recruitment in the study. * Upadacitinib prescribed in accordance to the applicable approved label and local regulatory and reimbursement policies. * French Participants Only: Taking oral glucocorticoids ≥5 mg/day of prednisone or equivalent for at least 3 months prior to study start.

Exclusion criteria

\- Prior treatment with Upadacitinib.

Design outcomes

Primary

Measure	Time frame	Description
Percentage of Participants Who Achieve Remission	At Month 6	Remission is defined as Disease Activity Score at 28 joints (DAS28) C-reactive Protein (CRP)\<2.6.
Percentage of Participants Who Achieve Remission at 6 Months and Maintain Remission	At Month 12	Remission is defined as DAS28-CRP\<2.6. Maintaining remission is defined as no more than 0.6 point increase in DAS28-CRP.

Secondary

Measure	Time frame	Description
Percentage of Participants Who Achieve Low Disease Activity (LDA) at 6 months that maintain LDA	Through Month 24	LDA is defined as DAS28-CRP≤3.2. Maintaining remission is defined as no more than 0.6 point increase in DAS28-CRP.
Percentage of Participants Who Achieve Remission at 3 Months and Maintain Remission	Through Month 24	Remission is defined as DAS28-CRP\<2.6. Maintaining remission is defined as no more than 0.6 point increase in DAS28-CRP.
Percentage of Participants Who Achieve Remission at 6 Months and Maintain Remission Grouped by Glucocorticoid Dose	At Month 12	Remission is defined as DAS28-CRP\<2.6. Maintaining remission is defined as no more than 0.6 point increase in DAS28-CRP.
Percentage of Participants Who Achieve LDA at 3 months that maintain LDA Grouped by Glucocorticoid Dose	Through Month 6	LDA is defined as DAS28-CRP≤3.2. Maintaining remission is defined as no more than 0.6 point increase in DAS28-CRP.
Percentage of Participants in LDA that Achieve Glucocorticoid Dose <5 mg/Day Per Visit	Through Month 24	LDA is defined as DAS28-CRP\<3.2.
Percentage of Participants in Remission that Achieve Glucocorticoid Dose <5 mg/Day Per Visit	Through Month 24	Remission is defined as DAS28-CRP\<2.6.
Percentage of Participants Who Initiated Upadacitinib as Combination Therapy (csDMARD +/- Glucocorticoids) That Moved to Monotherapy (+/- Glucocorticoids)	Through Week 24	Percentage of participants who initiated Upadacitinib as combination therapy (csDMARD +/- Glucocorticoids) that moved to monotherapy (+/- glucocorticoids).
Of the Participants Initiating Upadacitinib as Combination Therapy (csDMARD +/- Glucocorticoids) and Achieve Remission at 6 months, the Percentage of Participants that Maintain Remission Grouped by Maintenance of Combination Therapy Strategy	Through Month 24	Remission is defined as DAS28-CRP\<2.6.
Of the Participants Initiating Upadacitinib as Combination Therapy (csDMARD +/- Glucocorticoids) and Achieve LDA at 6 months, the Percentage of Participants that Maintain LDA Grouped by Maintenance of Combination Therapy Strategy	Through Month 24	LDA is defined as DAS28-CRP\<3.2.
Of the Participants Initiating Upadacitinib as Monotherapy Therapy (+/- Glucocorticoids) and Achieve Remission at 6 months, the Percentage of Participants that Maintain Remission Grouped by Maintenance of Monotherapy	Through Month 24	Remission is defined as DAS28-CRP\<2.6.
Percentage of Participants Who Achieved a Glucocorticoid Dose <5 mg/Day Without Conventional Synthetic Disease Modifying Anti Rheumatic Drug (csDMARD) Intensification	At Month 6	Percentage of participants who achieved a glucocorticoid dose \<5 mg/day without csDMARD intensification.
Percentage of Participants Who Do Not Achieve Remission at Any Point in the Study	Through Month 24	Remission is defined as DAS28-CRP\<2.6.
Time to the Discontinuation of Upadacitinib	Through Month 24	Time to the discontinuation of Upadacitinib.
Time to First Treatment Adjustment	Baseline (Month 0) Through Month 24	Treatment Adjustment is defined as treatment escalation/de-escalation/ addition/withdrawal.
Percentage of Participants Achieving LDA Grouped by Therapy Strategy	Through Month 24	LDA is defined as DAS28-CRP\<3.2, Simplified Disease Activity Index (SDAI) ≤11 and Clinical Disease Activity Index (CDAI) ≤10.
Percentage of Participants Achieving Remission Grouped by Therapy Strategy	Through Month 24	Remission is defined as DAS28-CRP\<2.6, SDAI≤3.3 and CDAI ≤2.8.
Change in Medication Burden Treatment Burden Questionnaire (TBQ) in Participants, Grouped by Therapy Strategy	Through Week 24	The TBQ is composed of 13 items rated on a Likert scale ranging from 0 (not a problem), to 10 (big problem). scores can be summed into a global score, ranging from 0 to 130.
Change in Physical Function Health Assessment Questionnaire - Disability Index (HAQ-DI) in Participants, Grouped by Therapy Strategy	Baseline (Month 0) Through Month 24	HAQ is a widely accepted, validated, rheumatology specific instrument to assess physical function in Rheumatoid Arthritis. It consists of 20 questions, covering eight types of activities. For each question, scores range from 0 to 3 (0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty or with assistance; 3 = unable to do). HAQ Disability Index (HAQ-DI) score is the average of the highest score in each of the eight categories.
Change in Pain Visual Analogue Scale (VAS) in participants, Grouped by Therapy Strategy	Baseline (Month 0) Through Month 24	A VAS is used to assess worst joint pain in the past 7 days.
Change in Morning Stiffness in Participants, Grouped by Therapy Strategy	Baseline (Month 0) Through Month 24	A numeric rating scale (NRS) is used to assess severity and length of morning stiffness in the past 7 days.
Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) in Participants, Grouped by Therapy Strategy	Baseline (Month 0) Through Month 24	The FACIT Fatigue Scale is a short, 13-item, easy to administer tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four-point Likert scale (0 = not at all fatigued to 4 = very much fatigued).
Of the Participants Initiating Upadacitinib as Monotherapy Therapy (+/- Glucocorticoids) and Achieve LDA at 6 months, the Percentage of Participants that Maintain LDA Grouped by Maintenance of Monotherapy	Through Month 24	LDA is defined as DAS28-CRP\<3.2.
Percentage of Participants Who Achieve Remission at 6 Months and Maintain Remission	At Month 24	Remission is defined as DAS28-CRP\<2.6. Maintaining remission is defined as no more than 0.6 point increase in DAS28-CRP.

Countries

Argentina, Australia, Austria, Belgium, France, Germany, Greece, Ireland, Israel, Italy, Kuwait, Mexico, Russia, Saudi Arabia, Spain, Switzerland, Taiwan, United Arab Emirates, Uruguay

Outcome results